Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 248)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
2 |
|
Calciferol |
|
Phase 4 |
|
|
|
3 |
|
Ramucirumab |
Approved, Investigational |
Phase 3 |
|
947687-13-0 |
|
Synonyms:
1121B
CYRAMZA
Cyramza®|IMC-1121B
|
IMC-1121B
LY3009806
Ramucirumab
|
|
4 |
|
Aminolevulinic acid |
Approved |
Phase 3 |
|
106-60-5 |
137 |
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
5 |
|
Panitumumab |
Approved, Investigational |
Phase 3 |
|
339177-26-3 |
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
6 |
|
Avelumab |
Approved, Investigational |
Phase 3 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
7 |
|
Topotecan |
Approved, Investigational |
Phase 2, Phase 3 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
8 |
|
Infigratinib |
Approved, Investigational |
Phase 3 |
|
872511-34-7 |
53235510 |
Synonyms:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
BGJ 398|BGJ-398|BGJ398|NVP-BGJ398|Truseltiq®
BGJ398
|
BGJ-398
INFIGRATINIB
MVP-BGJ398
NVP-BGJ398
|
|
9 |
|
Pembrolizumab |
Approved |
Phase 2, Phase 3 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
10 |
|
Lenvatinib |
Approved, Investigational |
Phase 2, Phase 3 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
11 |
|
BCG vaccine |
Approved, Investigational |
Phase 3 |
|
|
|
Synonyms:
BACILLUS CALMETTE GUERIN VACCINE
BACILLUS CALMETTE GUÉRIN VACCINE
Bacillus Calmette–Guérin (BCG) vaccine
|
Bacillus calmette-guerin live antigen, unspecified substrain
BCG
BCG vaccine
|
|
12 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
13 |
|
Gefitinib |
Approved, Investigational |
Phase 3 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
14 |
|
Ciprofloxacin |
Approved, Investigational |
Phase 3 |
|
85721-33-1, 93107-08-5 |
2764 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylate
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylIC ACID
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Anhydrous, ciprofloxacin hydrochloride
Bacquinor
BAY O 9867 FREE BASE
Baycip
BAY-O-9867 FREE BASE
BAYQ3939
BAY-Q-3939
Bernoflox
CETRAXAL
Ciflox
Cifloxin
CILOXAN
Ciprinol
Cipro
Cipro I.V.
Cipro XL
Cipro XR
CIPROBAY
|
Ciprocinol
Ciprodar
Ciprofloxacin
Ciprofloxacin dihydrochloride
Ciprofloxacin HCl
Ciprofloxacin hydrochloride
Ciprofloxacin hydrochloride anhydrous
Ciprofloxacin monohydrochloride
Ciprofloxacin monohydrochloride monohydrate
Ciprofloxacina
Ciprofloxacine
Ciprofloxacino
Ciprofloxacinum
Cipromycin
Ciproquinol
Ciproxan
Ciproxin
CPFX
CPR867
Flociprin
Floxin
Hydrochloride anhydrous, ciprofloxacin
Hydrochloride, ciprofloxacin
Monohydrate, ciprofloxacin monohydrochloride
Monohydrochloride monohydrate, ciprofloxacin
Ocuflox
OTIPRIO
Proquin XR
Septicide
VELMONIT
Velomonit
|
|
15 |
|
Cephalexin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
15686-71-2 |
27447 |
Synonyms:
(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
66873
7-(D-a-Aminophenylacetamido)desacetoxycephalosporanate
7-(D-a-Aminophenylacetamido)desacetoxycephalosporanic acid
7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanate
7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
7-(D-Α-aminophenylacetamido)desacetoxycephalosporanate
7-(D-Α-aminophenylacetamido)desacetoxycephalosporanic acid
7-b-(D-a-Amino-a-phenylacetylamino)-3-methyl-3-cephem-4-carboxylate
7-b-(D-a-Amino-a-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylate
7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
7-Β-(D-α-amino-α-phenylacetylamino)-3-methyl-3-cephem-4-carboxylate
7-Β-(D-α-amino-α-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
Anhydrous cefalexin
Anhydrous cephalexin
Cefalessina
Cefalexin
Cefalexin anhydrous
Cefalexina
Cefalexine
Céfalexine
Cefalexinum
Celexin
Cepastar
Cepexin
Cephacillin
CEPHALEXIN
Cephalexin 1-hydrate
Cephalexin anhydrous
|
Cephalexin dihydride
Cephalexin hemihydrate
Cephalexin hydrate
Cephalexin hydrochloride
Cephalexin monohydrate
Cephalexin monohydrochloride
Cephalexin monohydrochloride, monohydrate
Cephalexin, (6R-(6alpha,7alpha(r*)))-isomer
Cephalexin, (6R-(6alpha,7beta(s*)))-isomer
Cephalexin, (6R-(6alpha,7beta))-isomer
Cephalexin, monosodium salt
Cephalexin, monosodium salt, (6R-(6alpha,7beta))-isomer
Cephalexine
Cephalexinum
CEPOREX
Ceporexin
Ceporexine
CEX
Dihydride, cephalexin
Hemihydrate, cephalexin
Hydrochloride, cephalexin
KEFLET
Keflex
KEFTAB
Monohydrate cephalexin monohydrochloride
Monohydrate, cephalexin
Monohydrochloride, cephalexin
Monohydrochloride, monohydrate cephalexin
Monosodium salt cephalexin
Palitrex
|
|
16 |
|
Valrubicin |
Approved |
Phase 3 |
|
56124-62-0 |
41744 |
Synonyms:
(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8²-valerate
2,2,2-Trifluoro-N-(3-hydroxy-2-methyl-6-{[(1S,3S)-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-3-[2-(pentanoyloxy)acetyl]-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)ethanimidate
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
AD 32
AD-32
Antibiotic ad 32
NSC-246131
N-Trifluoroacetyladriamycin 14-valerate
|
Paladin brand OF valrubicin
VALRUBICIN
Valrubicina
Valrubicine
Valrubicinum
Valstar
VALSTAR PRESERVATIVE FREE
Valtaxin
|
|
17 |
|
Laevulinic Acid |
Experimental |
Phase 3 |
|
123-76-2 |
11579 |
Synonyms:
3-Acetylpropionate
3-Acetylpropionic acid
3-Ketobutane-1-carboxylate
3-Ketobutane-1-carboxylic acid
4-Ketovalerate
4-Ketovaleric acid
4-Oxopentanoate
4-Oxopentanoic acid
4-Oxovalerate
4-Oxovaleric acid
b-Acetylpropionate
b-Acetylpropionic acid
beta-Acetylpropionate
beta-Acetylpropionic acid
Calcium levulate
Calcium levulinate
Diasporal
FEMA NO. 2627
gamma-Ketovalerate
gamma-Ketovaleric acid
g-Ketovalerate
|
g-Ketovaleric acid
LAEVULINate
LAEVULINIC ACID
Laevulinsaeure
LEVA
Levulate
Levulic acid
Levulinate
Levulinic acid
Levulinic acid, ammonium salt
Levulinic acid, calcium salt
Levulinic acid, sodium salt
Levulinsaeure
Magnesium diasporal
Magnesium laevulinate
Magnesium levulinate
NSC-3716
Î’-acetylpropionate
Î’-acetylpropionic acid
Γ-ketovalerate
Γ-ketovaleric acid
|
|
18 |
|
Cediranib |
Investigational |
Phase 3 |
|
288383-20-0 |
9933475 |
Synonyms:
4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE
AZD 2171
AZD 2171|AZD2171|ZD 2171
AZD-2171
|
CEDIRANIB
RECENTIN
ZD 2171
ZD-2171
|
|
19 |
|
Maleic acid |
Experimental, Investigational |
Phase 3 |
|
110-16-7, 110-17-8 |
444266 444972 |
Synonyms:
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
Allomaleate
Allomaleic acid
Boletate
Boletic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
e297
FC 33
Fumarate
Fumaric acid
Fumaricum acidum
Fumarsaeure
|
Fumarsäure
Furamag
H2Male
Hydrogen maleate
Kyselina maleinova
Lichenate
Lichenic acid
MAE
Mafusol
Maleate
MALEIC ACID
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
|
|
20 |
|
Paclitaxel poliglumex |
Experimental, Investigational |
Phase 3 |
|
263351-82-2 |
|
Synonyms:
CT-2103
PACLITAXEL POLIGLUMEX
|
|
|
21 |
|
Carotenoids |
|
Phase 3 |
|
|
|
22 |
|
Hematinics |
|
Phase 3 |
|
|
|
23 |
|
BB 1101 |
|
Phase 3 |
|
|
|
24 |
|
Photosensitizing Agents |
|
Phase 3 |
|
|
|
25 |
|
topoisomerase I inhibitors |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Taxane |
|
Phase 3 |
|
|
108169 |
27 |
|
Anesthetics |
|
Phase 3 |
|
|
|
28 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Immune Checkpoint Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Liver Extracts |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
32 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
33 |
|
Fluoroquinolones |
|
Phase 3 |
|
|
|
34 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 3 |
|
|
|
35 |
|
interferons |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
37 |
|
Tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
38 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
39 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
40 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
41 |
|
Hydroxocobalamin |
Approved |
Phase 2 |
|
13422-51-0 |
15589840 44475014 |
Synonyms:
a-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
alpha Cobione
alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
ALPHAREDISOL
Axlon
Ciplamin H
Cobalex
Cobalin H
COBALIN-H
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole inner salt
Codroxomin
CYANOKIT
Docclan
Docelan
Docevita
Droxomin
Ducobee hy
Duradoce
|
Duralta-12
HEPAVIT
Hydrocobalamin
Hydrogrisevit
Hydrovit
Hydroxocobalamin
Hydroxo-cobalamin
HYDROXOCOBALAMIN ACETATE
HYDROXOCOBALAMIN ANHYDROUS
Hydroxocobalamine
HYDROXOCOBALAMINUM ANHYDROUS
HYDROXOCOBEMINE
Hydroxomin
Hydroxycobalamin
MEGAMILBEDOCE
NEO-CYTAMEN
OH-CBL
Vitamin b-12b
|
|
42 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
43 |
|
Mecobalamin |
Approved, Investigational |
Phase 2 |
|
13422-55-4 |
|
Synonyms:
ASIMIL B-12
B-MAX
CO-METHYLCOBALAMIN
MeCbl
Mecobalamin
Mecobalamina
|
Mecobalaminum
Methyl vitamin B12
Methyl(III)cobalamin
Methylcob(III)alamin
Methylcobalamin
|
|
44 |
|
Raloxifene |
Approved, Investigational |
Phase 2 |
|
82640-04-8, 84449-90-1 |
5035 |
Synonyms:
(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
Eviden
EVIREX
Evista
Evista®|LY-156758|Optruma®|raloxifene hydrochloride
J22.982B
Keoxifene
KEOXIFENE HCL
Keoxifene hydrochloride
LY 139481
LY-139481
LY156758
LY-156758
|
OPTRUMA
OSTIRAL
RAL
Raloxifene
Raloxifène
Raloxifene HCL
Raloxifene hydrochloride
Raloxifeno
Raloxifeno [Spanish]
Raloxifenum
Raloxifenum [Latin]
Raxeto
RAZYLAN
|
|
45 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Î’-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
46 |
|
Ifosfamide |
Approved |
Phase 2 |
|
3778-73-2 |
3690 |
Synonyms:
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Holoxan
Ifex
Ifosfamid
Ifosfamida
IFOSFAMIDE
Ifosfamide sterile
Ifosfamidum
Ifosphamide
Ifsofamide
Iphosphamid
|
Iphosphamide
I-phosphamide
Iso endoxan
Iso-endoxan
Isofosfamide
Isophosphamide
Isosfamide
MITOXANA
MJF-9325
NSC-109724
Z-4942
|
|
47 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 1, Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
48 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
49 |
|
Epirubicin |
Approved |
Phase 2 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
50 |
|
Arsenic trioxide |
Approved, Investigational |
Phase 2 |
|
1327-53-3 |
518740 |
Synonyms:
Acide Arsenieux
Acide Arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic oxidearsenous trioxide
Arsenic Sesquioxide
ARSENIC TRIOXIDE
Arsenic Trioxide [UN1561] [Poison]
Arsenic(III) oxide
Arsenic, White
arsénico trióxido
Arsenicum Album
Arsenigen Saure
Arsenigen Saure [German]
Arsenious acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious trioxide
Arsenite
|
Arsenolite
Arsenous Acid
Arsenous Acid Anhydride
Arsenous anhydride
Arsenous Oxide
Arsenous Oxide Anhydride
Arsentrioxide
Arsodent
Claudelite
Claudetite
Crude Arsenic
Diarsenic oxide
Diarsenic trioxide
Di-Arsenic Trioxide
Diarsonic Trioxide
HSDB 419
Naonobin
Oxyde Arsenieux [ISO-French]
Poison Flour
TRISENOX
Trixenox
White Arsenic
|
|
Interventional clinical trials:
(show top 50)
(show all 546)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Pilot Study of the Biological Effects of Vitamin D in Patients With Resectable Urinary Tract Urothelial Carcinoma |
Completed |
NCT04197089 |
Phase 4 |
Vitamin D |
2 |
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma |
Not yet recruiting |
NCT05488353 |
Phase 4 |
Disitamab Vedotin for Injection,Penpulimab Injection |
3 |
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? |
Unknown status |
NCT00719303 |
Phase 3 |
|
4 |
A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium |
Unknown status |
NCT01830231 |
Phase 2, Phase 3 |
Cabazitaxel;Vinflunine |
5 |
Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study |
Unknown status |
NCT00146276 |
Phase 3 |
gemcitabine |
6 |
Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - |
Unknown status |
NCT03296306 |
Phase 3 |
Treatment duration of cisplatin based chemotherapy |
7 |
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer |
Unknown status |
NCT01993979 |
Phase 3 |
Chemotherapy |
8 |
A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression |
Unknown status |
NCT03193788 |
Phase 3 |
pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone |
9 |
A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma |
Completed |
NCT00951496 |
Phase 3 |
Carboplatin;Cisplatin;Paclitaxel |
10 |
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
Completed |
NCT00262847 |
Phase 3 |
Carboplatin;Paclitaxel |
11 |
Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study |
Completed |
NCT00867347 |
Phase 3 |
|
12 |
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy |
Completed |
NCT00389155 |
Phase 2, Phase 3 |
Vinflunine;Gemcitabine |
13 |
Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. |
Completed |
NCT01668459 |
Phase 2, Phase 3 |
Cabazitaxel |
14 |
Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder |
Completed |
NCT00028756 |
Phase 3 |
doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin |
15 |
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma |
Completed |
NCT00942331 |
Phase 3 |
Cisplatin;Gemcitabine Hydrochloride |
16 |
Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract |
Completed |
NCT00315237 |
Phase 3 |
vinflunine and best supportive care |
17 |
A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse |
Completed |
NCT00003701 |
Phase 3 |
carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate |
18 |
Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder |
Completed |
NCT00014534 |
Phase 3 |
cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride |
19 |
Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder |
Completed |
NCT00003623 |
Phase 3 |
|
20 |
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma |
Completed |
NCT02793128 |
Phase 3 |
UGN-101 instillations |
21 |
A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine |
Completed |
NCT02101931 |
Phase 3 |
Amino levulinic Acid |
22 |
A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder |
Completed |
NCT00330499 |
Phase 3 |
Cisplatin |
23 |
A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy |
Completed |
NCT03410693 |
Phase 2, Phase 3 |
Rogaratinib (BAY1163877);Chemotherapy |
24 |
Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy |
Completed |
NCT00014274 |
Phase 2, Phase 3 |
carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate |
25 |
A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) |
Completed |
NCT03374488 |
Phase 3 |
Pembrolizumab;Epacadostat;Placebo |
26 |
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy |
Completed |
NCT00022191 |
Phase 3 |
cisplatin;gemcitabine hydrochloride;paclitaxel |
27 |
Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium |
Completed |
NCT00003376 |
Phase 3 |
carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine |
28 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy |
Completed |
NCT02426125 |
Phase 3 |
Ramucirumab;Docetaxel;Placebo |
29 |
A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) |
Completed |
NCT03361865 |
Phase 3 |
Pembrolizumab;Epacadostat;Placebo |
30 |
Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study |
Completed |
NCT02818725 |
Phase 3 |
Chemotherapy;Panitumumab |
31 |
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma |
Completed |
NCT02853305 |
Phase 3 |
Cisplatin;Carboplatin;Gemcitabine |
32 |
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy |
Recruiting |
NCT04575935 |
Phase 3 |
Chemotherapy |
33 |
Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial |
Recruiting |
NCT04574960 |
Phase 3 |
Gemcitabine;Cisplatin;Carboplatin |
34 |
A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy |
Recruiting |
NCT04579224 |
Phase 3 |
Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel |
35 |
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE) |
Recruiting |
NCT04637594 |
Phase 3 |
Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab |
36 |
A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence |
Recruiting |
NCT05136898 |
Phase 3 |
UGN-102 |
37 |
A Randomized Trial Comparing Intravesical Gemcitabine to Continuous Bladder Irrigation With Sterile Water to Prevent Bladder Cancer Implantation in Patients Undergoing Excision of Upper Tract Urothelial Carcinoma |
Recruiting |
NCT04865939 |
Phase 3 |
Gemcitabine |
38 |
A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing |
Recruiting |
NCT05302284 |
Phase 3 |
RC48-ADC;Toripalimab;Gemcitabine;Cisplatin;Carboplatin |
39 |
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence |
Recruiting |
NCT05243550 |
Phase 3 |
UGN-102 |
40 |
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
Recruiting |
NCT03967977 |
Phase 3 |
Tislelizumab;Placebo;Cisplatin;Gemcitabine Hydrochloride;Carboplatin |
41 |
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer |
Recruiting |
NCT05092958 |
Phase 3 |
Avelumab;Cabozantinib S-malate |
42 |
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) |
Active, not recruiting |
NCT00565851 |
Phase 3 |
Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel |
43 |
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy |
Active, not recruiting |
NCT00108745 |
Phase 3 |
Paclitaxel;Paclitaxel Poliglumex |
44 |
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT02446600 |
Phase 3 |
Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride |
45 |
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) |
Active, not recruiting |
NCT02502266 |
Phase 2, Phase 3 |
Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride |
46 |
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 |
Active, not recruiting |
NCT01167712 |
Phase 3 |
Carboplatin;Paclitaxel |
47 |
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) |
Active, not recruiting |
NCT03898180 |
Phase 3 |
Lenvatinib;Placebo for lenvatinib |
48 |
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer |
Active, not recruiting |
NCT03091660 |
Phase 3 |
|
49 |
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG IR NMIBC) |
Active, not recruiting |
NCT04688931 |
Phase 3 |
UGN-102 |
50 |
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) |
Active, not recruiting |
NCT04197986 |
Phase 3 |
Infigratinib;Placebo |
|